Exertional desaturation is an important predictor of mortality in patients with interstitial lung disease. We evaluated the prevalence of exertional desaturation in subjects with interstitial lung disease and determined its relationship with the prescription of ambulatory oxygen therapy.
METHODS:
Our retrospective analysis examined prospectively collected data from interstitial lung disease registries of 2 Melbourne hospitals: Alfred Health and Austin Health. All patients with baseline the 6-min walk tests on room air were included. We evaluated the prescription of ambulatory oxygen therapy, up to 3 months after 6-min walk tests, among those with exertional desaturation.
RESULTS:
Of the 400 subjects, 214 (54%) had exertional desaturation. The prevalence of desaturation increased with the severity of lung function impairment (FVC measurement: 33% for > 75% predicted, 69% for 50–75% predicted, 86% for < 50% predicted; diffusing capacity of the lung for carbon monoxide measurement: 20% for > 55% predicted, 64% for 36–55% predicted, 93% for ≤ 35% predicted, P < .001 for both severity classifications). There was no difference in the prevalence of exertional desaturation among common disease subtypes (P = .17). Among the desaturators, 14 (7%) had resting hypoxemia and all were prescribed long-term oxygen therapy. Of the remaining 200 with exertional desaturation only, 58 (29%) were prescribed ambulatory oxygen therapy. Multiple logistic regression showed independent associations between the ambulatory oxygen therapy prescription and shorter 6-min walk distance (P < .001) as well as worse FVC (% predicted, P = .037).
CONCLUSIONS:
Exertional desaturation is common in subjects with interstitial lung disease. More severely impaired exercise capacity and worse lung function are associated with the prescription of ambulatory oxygen therapy in interstitial lung disease.
KingTEJr, ToozeJA, SchwarzMI, BrownKR, CherniackRM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med, 2001; 164(7):1171–1181.
2.
LamaVN, FlahertyKR, ToewsGB, ColbyTV, TravisWD, LongQ, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med, 2003; 168(9):1084–1090.
3.
HallstrandTS, BoitanoLJ, JohnsonWC, SpadaCA, HayesJG, RaghuG. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J, 2005; 25(1):96–103.
4.
FlahertyKR, AndreiAC, MurrayS, FraleyC, ColbyTV, TravisWD, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med, 2006; 174(7):803–809.
5.
WallaertB, MongeE, Le RouzicO, Wémeau-StervinouL, SalleronJ, GrosboisJM. Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia. Chest, 2013; 144(5):1652–1658.
6.
HerridgeJ, YuillK, KendrickAH. Does the six-minute walk test predict survival at one year and in the longer term in patients idiopathic pulmonary fibrosis (IPF)?. Thorax, 2016; 71(Suppl 3):A239–A240.
7.
NishiyamaO, TaniguchiH, KondohY, KimuraT, KatoK, OgawaT, et al. Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD. Resp Med, 2007; 101(4):833–838.
8.
HardingeM, AnnandaleJ, BourneS, CooperB, EvansA, FreemanD, et al. British Thoracic Society Home Oxygen Guideline Development Group; British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for home oxygen use in adults. Thorax, 2015; 70(Suppl 1):i1–i43.
9.
McDonaldCF, WhyteK, JenkinsS, SerginsonJ, FrithP. Clinical practice guideline on adult domiciliary oxygen therapy: executive summary from the Thoracic Society of Australia and New Zealand. Respirology, 2016; 21(1):76–78.
10.
SharpC, AdamaliH, MillarAB. Ambulatory and short-burst oxygen for interstitial lung disease. Cochrane Database Syst Rev, 2016; 7:CD011716.
ViscaD, MoriL, TsipouriV, CanuS, BoniniM, PavittM, et al. AmbOx: a randomised controlled, crossover trial evaluating the effects of ambulatory oxygen on health status in patients with fibrotic interstitial lung disease. Am J Resp Crit Care, 2017; 195:A7603.
13.
HollandAE, SpruitMA, TroostersT, PuhanMA, PepinV, SaeyD, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J, 2014; 44(6):1428–1446.
14.
CorteTJ, WortSJ, TalbotS, MacdonaldPM, HansellDM, PolkeyM, et al. Elevated nocturnal desaturation index predicts mortality in interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis, 2012; 29(1):41–50.
15.
LettieriCJ, NathanSD, BrowningRF, BarnettSD, AhmadS, ShorrAF. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med, 2006; 100(10):1734–1741.
16.
AgustíAG, RocaJ, GeaJ, WagnerPD, XaubetA, Rodriguez-RoisinR. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis, 1991; 143(2):219–225.
RaghuG, NathanSD, BehrJ, BrownKK, EganJJ, KawutSM, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J, 2015; 46(5):1370–1377.
19.
BoutouAK, PitsiouGG, TrigonisI, PapakostaD, KontouPK, ChavouzisN, et al. Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension. Respirology, 2011; 16(3):451–458.
20.
FulmerJD, RobertsWC, von GalER, CrystalRG. Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J Clin Invest, 1979; 63(4):665–676.
21.
AgustiAG, RocaJ, Rodriguez-RoisinR, XaubetA, Agusti-VidalA. Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J, 1988; 1(6):510–516.
22.
ChinetT, JaubertF, DusserD, DanelC, ChrétienJ, HuchonGJ. Effects of inflammation and fibrosis on pulmonary function in diffuse lung fibrosis. Thorax, 1990; 45(9):675–678.
23.
NoblePW, AlberaC, BradfordWZ, CostabelU, GlassbergMK, KardatzkeD, et al.; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet, 2011; 377(9779):1760–1769.
24.
KingTEJr, BradfordWZ, Castro-BernardiniS, FaganEA, GlaspoleI, GlassbergMK, et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 2014; 370(22):2083–2092.
25.
HyldgaardC. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival. Dan Med J, 2015; 62(4):B5069.
26.
SiebelingL, PuhanMA, MuggensturmP, ZollerM, Ter RietG. Characteristics of Dutch and Swiss primary care COPD patients – baseline data of the ICE COLD ERIC study. Clin Epidemiol, 2011; 3:273–283.
27.
TashkinDP, CelliB, SennS, BurkhartD, KestenS, MenjogeS, DecramerM. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 2008; 359(15):1543–1554.
28.
WiseRA, AnzuetoA, CottonD, DahlR, DevinsT, DisseB. TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med, 2013; 369(16):1491–1501.
29.
LacasseY, BernardS, MaltaisF. Eligibility for home oxygen programs and funding across Canada. Can Respir J, 2015; 22(6):324–330.
30.
KhorYH, GohNSL, McDonaldCF, HollandAE. Oxygen therapy for interstitial lung disease: physicians' perceptions and experiences. Ann Am Thorac Soc, 2017; 14(12):1772–1778.
31.
EatonT, GarrettJE, YoungP, FergussonW, KolbeJ, RudkinS, WhyteK. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. Eur Respir J, 2002; 20(2):306–312.
32.
KhorYH, GohNSL, McDonaldCF, HollandAE. Oxygen therapy for interstitial lung disease: a mismatch between patient expectations and experiences. Ann Am Thorac Soc, 2017; 14(6):888–895.
33.
VillalbaWO, Sampaio-BarrosPD, PereiraMC, CerqueiraEM, LemeCAJr., Marques-NetoJF, PaschoalIA. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest, 2007; 131(1):217–222.
34.
DelourmeJ, Stervinou-WemeauL, SalleronJ, GrosboisJM, WallaertB. Six-minute stepper test to assess effort intolerance in interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis, 2012; 29(2):107–112.
35.
JenkinsS, ČečinsN. Six-minute walk test: observed adverse events and oxygen desaturation in a large cohort of patients with chronic lung disease. Intern Med J, 2011; 41(5):416–422.
36.
PoulainM, DurandF, PalombaB, CeugnietF, DesplanJ, VarrayA, PréfautC. 6-minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD. Chest, 2003; 123(5):1401–1407.
37.
HsiaD, CasaburiR, PradhanA, TorresE, Porszasz. Physiological responses to linear treadmill and cycle ergometer exercise in COPD. Eur Respir J, 2009; 34(3):605–615.
38.
MahlerDA, GiffordAH, WatermanLA, WardJ, MachalaS, BairdJC. Mechanisms of greater oxygen desaturation during walking compared with cycling in patients with COPD. Chest, 2011; 140(2):351–358.
39.
SolwayS, BrooksD, LacasseY, ThomasS. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest, 2001; 119(1):256–270.
40.
EnrightPL, McBurnieMA, BittnerV, TracyRP, McNamaraR, ArnoldA, NewmanAB. Cardiovascular Health Study. The 6-min walk test: a quick measure of functional status in elderly adults. Chest, 2003; 123(2):387–398.
